Of note, the new pan-TRK inhibitors entrectinib and LOXO-101 are now being tested in clinical trials in patients with solid tumors and have already yielded dramatic clinical activity in some patients, demonstrating that some human cancers are TRK dependent [13, 25, 33, 34], and TRKs may be good targets for molecular therapy. The gene discussed is NTRK1; the disease is cancer.